Histologically confirmed, new diagnosis of PTCL
COHORT D: Histologically confirmed diagnosis of melanoma
Histologically or cytologically confirmed diagnosis of metastatic medullary thyroid cancer
Histologically or cytologically confirmed diagnosis of melanoma.
Histologically or cytologically confirmed diagnosis of melanoma
Histologically confirmed diagnosis of GIST
histologically confirmed diagnosis of metastatic CRPC
Histologically or cytologically confirmed diagnosis of prostate cancer
Histologically confirmed diagnosis of one of the following:
Histologically confirmed diagnosis of cHL.
Histologically or cytologically confirmed diagnosis of early stage prostate cancer
Patients must have histologically confirmed new diagnosis of breast cancer
have a histologically confirmed diagnosis of ER+ breast cancer;
Histologically confirmed diagnosis of RCC
Have histologically or cytologically confirmed diagnosis of pancreatic carcinoma
Pathologically confirmed diagnosis of cancer
Histologically confirmed diagnosis of melanoma
Histologically confirmed diagnosis of cancer as per the cohort specifications
Histologically confirmed diagnosis of epithelial cancer; subject must have a measurable disease for enrollment consideration
Histologically confirmed diagnosis of invasive cervical cancer
Histologically confirmed diagnosis of chordoma or chondrosarcoma
Histologically confirmed diagnosis of prostate cancer.
Histologically confirmed diagnosis of HCC
Histologically confirmed diagnosis of a CD20+ B-cell malignancy;
Subjects with histologically confirmed diagnosis of recurrent germ cell tumor
On primary diagnosis, patients must have had histologically confirmed adenocarcinoma of the colon or rectum; metastasis or recurrence do not need to be histologically confirmed
Must have histologically confirmed diagnosis of MPNST
Patients with a histologically-confirmed diagnosis of melanoma who have imaging findings suggestive of 1 to 4 brain metastases
Patients with a histologically or cytologically confirmed diagnosis of breast cancer; patients must have metastatic HER2 positive (+) disease
Subject has a definitive histologically or cytologically confirmed diagnosis of HER2(-) metastatic breast cancer.
Histologically-confirmed disease
Histologically or cytologically confirmed diagnosis of pancreatic cancer.
Histologically confirmed diagnosis of DLBCL
Histologically confirmed diagnosis of FL or MCL according to WHO 2008
Confirmed diagnosis of HER2 positive disease
Histologically confirmed diagnosis of melanoma
Histologically or cytologically confirmed diagnosis of HCC
Confirmed diagnosis of HER2 positive disease
Histologically confirmed diagnosis of malignant melanoma.
Histologically or cytologically confirmed diagnosis of metastatic uveal melanoma (mUM)
Patients must have a histologically confirmed diagnosis of Ph+ ALL
Histologically confirmed diagnosis of FL grade 3b.
Histologically or cytologically confirmed diagnosis
Histologically confirmed diagnosis of melanoma
Patients must have histologically or cytologically confirmed diagnosis of cancer not amenable to curative therapy.
Histologically confirmed diagnosis of prostate cancer
Histologically confirmed diagnosis of classical HL
Histologically or cytologically confirmed diagnosis of CRC
Histologically confirmed:
Patient has a histologically and/or cytologically confirmed diagnosis of breast cancer
Participants must have histologically or cytologically confirmed diagnosis of SCLC
Prior diagnosis of HCC confirmed histologically.
Histologically confirmed diagnosis of PTCL
Cytopathologically or histologically confirmed diagnosis of MM
Histologically confirmed diagnosis of conventional chondrosarcoma of any grade.
Histologically or cytologically confirmed diagnosis of mCRC
Histologically confirmed diagnosis of myeloma
Histologically confirmed diagnosis, measurable disease and evidence of disease progression of MM.
Histologically or cytologically confirmed diagnosis of prostate cancer
Have a confirmed diagnosis of cancer
Histologically confirmed cancer diagnosis
Histologically confirmed diagnosis for which an allogeneic transplant is utilized
Histologically and/or cytologically confirmed diagnosis of ER+/HER2- breast cancer
Must have a histologically confirmed cancer diagnosis
Have histologically confirmed cancer
Have a histologically-confirmed diagnosis of breast cancer
Histologically confirmed diagnosis of prostate cancer
Histologically confirmed:
Histologically confirmed diagnosis of adenocarcinoma of the rectum
Histologically or cytologically confirmed prostate cancer
Participants must have histologically or cytologically confirmed adenocarcinoma of the colon or rectum
Participants must have histologically or cytologically confirmed adenocarcinoma of the rectum
Histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically- or cytologically-confirmed diagnosis of adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the EGJ
Histologically confirmed adenocarcinoma of the breast
Histologically or cytologically confirmed adenocarcinoma of the prostate previously treated with surgery and/or radiotherapy.
Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate
Histologically or cytologically confirmed PSCC
Histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma; patients without histologically confirmed adenocarcinoma may be eligible if both the treating physician and the study principal investigator (PI) agree that the patient’s history is unambiguously indicative of advanced adenocarcinoma
Patients must have histologically or cytologically confirmed metastatic or unresectable adenocarcinoma of the colon or rectum
Histologically or cytologically confirmed adenocarcinoma of the prostate and the availability archival prostate tumor sample is required
Participants with histologically or cytologically confirmed diagnosis of adenocarcinoma of the GEJ or stomach will be enrolled in this study
Histologically or cytologically confirmed adenocarcinoma of the colon or the rectum that is metastatic or unresectable.
Histologically and cytologically documented diagnosis as gastroesophageal adenocarcinoma.
Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically or cytologically confirmed adenocarcinoma of prostate.
Histologically or cytologically confirmed prostate carcinoma.
Has histologically or cytologically documented adenocarcinoma NSCLC.
Histologically or cytologically confirmed adenocarcinoma of the prostate.
Has histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate;
Subjects must have histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically or cytologically confirmed adenocarcinoma of the breast with unresectable or metastatic disease
Histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically or cytologically confirmed adenocarcinoma of the prostate
New diagnosis of histologically confirmed adenocarcinoma of the rectum
Histologically or cytologically confirmed adenocarcinoma of the prostate (the availability archival prostate tumor sample is preferred not required)
Histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically or cytologically confirmed
Histologically or cytologically confirmed adenocarcinoma of the breast
Histologically or cytologically confirmed adenocarcinoma of the prostate (excluding predominant small cell histology)
Histologically or cytologically confirmed adenocarcinoma of the prostate
Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically confirmed metastatic adenocarcinoma of the lung
Histologically or cytologically confirmed prostate adenocarcinoma
Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
Histologically confirmed adenocarcinoma of the rectum
Histologically or cytologically proven adenocarcinoma of the colon or rectum
The subject has histologically or cytologically proven adenocarcinoma of the breast that is HER2+
The patient has histologically, or cytologically, confirmed adenocarcinoma of the prostate.
Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate
Histologically or cytologically confirmed diagnosis of biliary tract adenocarcinoma/cholangiocarcinoma
Histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma; patients without histologically confirmed adenocarcinoma may be eligible if both the treating physician and the study principal investigator (PI) agree that the patient’s history is unambiguously indicative of advanced adenocarcinoma
Histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically or cytologically confirmed carcinoma of the prostate
Histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically or cytologically confirmed adenocarcinoma of the prostate
Participants must have histologically or cytologically confirmed adenocarcinoma of the prostate
Diagnosis of histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum.
Histologically or cytologically confirmed adenocarcinoma of the prostate
Histologically or cytologically confirmed adenocarcinoma of the prostate at either MSKCC or at the participating site
I 01. Histologically- or cytologically-confirmed prostate adenocarcinoma.
Histologically or cytologically confirmed HER2-negative adenocarcinoma of the breast
Histologically or cytologically confirmed adenocarcinoma of the colon or rectum that is metastatic.
Histologically or cytologically confirmed prostate cancer
Histologically or cytologically confirmed adenocarcinoma of the prostate.
Histologically or cytologically confirmed adenocarcinoma consistent clinically with androgen independent prostate cancer
Histologically or cytologically proven adenocarcinoma of the breast
Diagnosis of histologically or cytologically confirmed prostate adenocarcinoma.
Histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum
Histologically or cytologically proven adenocarcinoma of the prostate
Histologically or cytologically confirmed adenocarcinoma of the breast.
Patient must have histologically or cytologically confirmed colorectal adenocarcinoma or small bowel adenocarcinoma
Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma, surgically castrated or continuous medical castration (for >=8 weeks prior to Screening)
Histologically or cytologically confirmed adenocarcinoma of the prostate;
The participant has histologically or cytologically confirmed, nonsquamous (adenocarcinoma/large cell or other) NSCLC.
Histologically or cytologically confirmed adenocarcinoma of the prostate;
Have a histologically or cytologically-confirmed diagnosis of adenocarcinoma of the GEJ or stomach
Histologically or cytologically confirmed unresectable or metastatic esophagogastric adenocarcinoma
Histological or cytologically confirmed prostate adenocarcinoma
Has histologically or cytologically documented adenocarcinoma NSCLC
The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination
Histologic documentation of invasive adenocarcinoma of the breast
There must be histologic confirmation of a diagnosis of colorectal adenocarcinoma.
Males diagnosed with histologically confirmed, adenocarcinoma of the prostate based on core biopsy prior to study entry from transrectal ultrasonography (TRUS)
Patients with cytologic evidence of adenocarcinoma in situ
Histologic confirmation of adenocarcinoma of the prostate
Histologic confirmation of prostate adenocarcinoma diagnosis
Evidence of neuroendocrine tumor, duodenal adenocarcinoma, or ampullary adenocarcinoma
Histological proof of adenocarcinoma of the prostate
Diagnosis of pancreatic islet neoplasm, acinar cell carcinoma, non- adenocarcinoma (i.e., lymphoma, sarcoma), adenocarcinoma originating from the biliary tree, or cystadenocarcinoma
Must have histologic or cytologic confirmation of recurrent metastatic pancreatic adenocarcinoma based on standard diagnostic criteria. Recurrence must be documented by diagnostic biopsy.
Does not have a diagnosis of prostate adenocarcinoma
Histologic confirmation of diagnosis of adenocarcinoma of the prostate will be required by biopsy
Documented pathologic confirmation of prostate adenocarcinoma
Patients must have histologic or cytologic confirmation of the diagnosis of invasive adenocarcinoma of the breast.
Patients with a histologic diagnosis of adenocarcinoma of the esophagus located distal to the carina
Histologically proven adenocarcinoma of the prostate obtained within 6 months of screening; patients in whom a diagnosis of high-risk localized or locally-advanced prostatic adenocarcinoma is suspected based on a serum PSA > 20 ng/mL or clinical T3 disease by digital rectal examination, but who have not yet undergone diagnostic prostate biopsy, will be eligible for screening and initial MRI and targeted prostate cancer biopsies which will be obtained at the same time as diagnostic biopsies; those patients in whom the diagnostic biopsies confirm prostatic adenocarcinoma will be permitted to continue with study treatment if they meet all additional eligibility criteria
Have histologically proven adenocarcinoma of the colon or rectum
Patients with adenocarcinoma of the prostate that in the opinion of the urologist could be resected after response to systemic therapy; ductal adenocarcinoma is permitted
Patients with cytologic evidence of adenocarcinoma in situ
No histologic documentation of breast adenocarcinoma
Must have operable gastric adenocarcinoma, T2-T4a, N0-N3, M0
Histologic confirmation of invasive adenocarcinoma originating in the breast
Histological or cytologic evidence of adenocarcinoma of the prostate confirmed at local institution
Diagnosis of adenocarcinoma of the prostate, confirmed by H. Lee (L.) Moffitt Cancer Center review
HER2 expressing adenocarcinoma of the esophagus centrally
Histologically documented adenocarcinoma (including the histologic variants of adenocarcinoma) of the colon or rectum
adenocarcinoma of the prostate that has been surgically treated with a post-treatment PSA that is undetectable;
Part B: Esophagogastric Adenocarcinoma:
Prior history of invasive adenocarcinoma of colon or rectum.
Patients with adenocarcinoma of unknown primary are excluded
Appendiceal adenocarcinoma basket\r\n* Metastatic appendiceal adenocarcinoma\r\n* Not considered candidate for curative surgery
Histologic confirmation of adenocarcinoma of the prostate by biopsy;
Patients with a histologic diagnosis of adenocarcinoma of the prostate
Participants with adenocarcinoma of the esophagus are excluded.
Evidence or history of metastatic adenocarcinoma of the prostate
Pathologically confirmed adenocarcinoma of the lung.
Grade 3 adenocarcinoma
Histologically documented diagnosis of adenocarcinoma of the prostate (PCa) with no histologic variants
Histologic proof of prostate adenocarcinoma
Histologic variants in the primary tumor (histologic variants other than adenocarcinoma)
Histologic diagnosis of adenocarcinoma of the prostate
Histologic or cytologic diagnosis of pancreas adenocarcinoma advanced or recurrent (stage III or IV) that is unresectable; histologic or cytologic pathology from any prior surgery is sufficient for diagnosis
Patients with a histologic diagnosis of adenocarcinoma of the upper gastrointestinal tract and hepatobiliary system, including patients with any of the following diagnoses and settings who are candidates to receive radiation with concurrent continuous infusion 5-FU or oral capecitabine chemotherapy:\r\n * Pancreatic adenocarcinoma (unresected or adjuvant)\r\n * Duodenal adenocarcinoma (unresected or adjuvant)\r\n * Extra-hepatic cholangiocarcinoma (unresected or adjuvant)\r\n * Gastric adenocarcinoma (unresected or adjuvant)\r\n * Gastroesophageal junction adenocarcinoma (adjuvant)
Patients with a histologic diagnosis of adenocarcinoma of the prostate
Patients with verrucous or adenocarcinoma
Diagnosis of pancreatic islet neoplasm, acinar cell carcinoma, non-adenocarcinoma (eg, lymphoma, sarcoma), adenocarcinoma originating from the biliary tree or cystadenocarcinoma
Histologic variants other than adenocarcinoma in the primary tumor
Diagnosis of pancreatic islet neoplasm, acinar cell carcinoma, non-adenocarcinoma, adenocarcinoma originating from the biliary tree or cystadenocarcinoma
Have a history of a primary adenocarcinoma of the colon and / or rectum
Prior to randomization, have histological confirmation that CRC lesions were adenocarcinoma (subtypes of adenocarcinoma, e.g. mucinous adenocarcinoma are allowed). Subjects with CRC lesions of other histological types, including mixed type with predominant adenocarcinoma, will not be eligible to be randomized to study treatment.
The subject has a proven histologic diagnosis of prostate adenocarcinoma, but may have undergone prior surgery and/or radiation
LUNG ADENOCARCINOMA COHORT (COHORT 3 ONLY): Subjects must have histologically confirmed advanced (stage IIIB/IV) lung adenocarcinoma; the diagnosis will be confirmed by the Laboratory of Pathology/CCR/NCI
Adenocarcinoma of the breast.
Histologic proof of adenocarcinoma of the prostate with clinical evidence of metastatic disease to the bone
Histologically-documented prostatic adenocarcinoma in >= 2 cores
Histologic diagnosis of prostate adenocarcinoma plus > 50% immunohistochemical staining for neuroendocrine markers (chromogranin, synaptophysin or neuron specific enolase)
Histologic confirmation of adenocarcinoma of the prostate
Histologic documentation of adenocarcinoma of the prostate
NON-RANDOMIZED OBSERVATIONAL COMPONENT ELIGIBILITY:\r\nHistologically-documented localized (stage < T3) prostate adenocarcinoma
Histologic confirmation of adenocarcinoma of the prostate
Carry a diagnosis of metastatic colon, rectum, or small bowel adenocarcinoma
Patients with evidence of concurrent adenocarcinoma-in-situ
The subject has a diagnosis of adenocarcinoma of the prostate
Patients with a histologic diagnosis of adenocarcinoma of the esophagus located distal to the carina
Diagnosis of adenocarcinoma of the prostate, confirmed by transrectal ultrasound (TRUS) biopsy
Diagnosis of prostate adenocarcinoma by transrectal ultrasound (TRUS)-guided biopsy between 28 to 90 days prior to enrollment
Patients must have histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC); pathologic confirmation is mandated before initiation of any protocol specified imaging studies or drug administrations; it is recognized that for some patients, histologic or cytologic confirmation of cancer may be obtained following study enrollment; patient volunteers to the DW- and DCE-MRI sequence parameter optimization imaging portion of the study are eligible if they have any pancreatic lesion, histologic or cytologic confirmation of pathology is not required for this patient volunteer group
Any non-adenocarcinoma histologic component
Biliary tract adenocarcinoma.
adenocarcinoma of the colon or rectum
Rectal tumor at baseline which would be considered to require complete TME
No prior chemotherapy or surgery for rectal cancer
Recurrent rectal cancer
Diagnosis of rectal adenocarcinoma
Entire tumor must be in the colon (rectal involvement is an exclusion); surgeon confirmation that entire tumor was located in the colon is required only in cases where it is important to establish if the tumor is a colon versus (vs.) rectal primary
History and physical including a digital rectal exam 60 days prior to registration
Subjects may not have a history of rectal surgery or lower gastrointestinal bleed
No prior therapy for rectal cancer.
Patients must have histologically or cytologically confirmed A) low lying (i.e. =< 6 cm from the anal verge) rectal adenocarcinoma eligible for concurrent chemoradiation therapy to rectal tumor, B) if the treatment is palliative in the metastatic setting, no additional requirements for tumor size or nodal involvement is needed; C) if the treatment is in the neoadjuvant setting, the tumor must ALSO be high-risk locally advanced rectal cancer defined as T3-4, N+, and/or at risk for a positive radial margin (as determined by the surgeon)
Primary resectable rectal cancer
No prior pelvic radiotherapy, chemotherapy, immunotherapy, or other anti-cancer treatment for rectal cancer
Previous radiotherapy in the pelvic region (eg, prostate) or previous rectal surgery (eg, total mesorectal excision [TME]) or any investigational treatment for rectal cancer
For male subjects, the digital rectal examination must not be suspicious for carcinoma of the prostate.
Clinical stage T4 (invasion into rectum or ureters) significantly increases the morbidity of the surgery\r\n* Patients with rectal or ureteral invasion will be considered to have unresectable disease
Histologically confirmed diagnosis of colon or rectal adenocarcinoma of any clinical stage, previously untreated with chemotherapy or radiotherapy, with a plan to undergo surgical resection no sooner than 7 days from the projected date of study drug initiation
No clinically detectable (MR, endoscopy or digital rectal examination [DRE]) tumor present
Prior radiation therapy, chemotherapy or extirpative surgery for rectal cancer
Rectal cancer located within 10 cm from the anal verge based on proctoscopy and digital rectal examination (DRE)
Rectal cancer staged as T4 by pelvic MRI
Severely symptomatic rectal tumors (near-completely obstructing, symptomatic bleeding)
Prior history of rectal resection
Gross residual disease in the prostate fossa appreciated wither on digital rectal examination (DRE) or on imaging, unless biopsy proven not to contain cancer
History of rectal surgery
History of rectal fistula
Biopsy-proven diagnosis of rectal adenocarcinoma
Histologically confirmed invasive well-moderately differentiated rectal adenocarcinoma diagnosed within 90 days prior to enrollment.
Prior treatment for rectal cancer.
Patients with biopsy-proven adenocarcinoma, stage II- IV rectal cancer.
Patients must be candidates for planned surgical resection of their primary rectal cancer 8 - 12 weeks after completion of neoadjuvant chemoRT, even if stage IV.
Histologically proven rectal cancer
Patient is a candidate for elective rectal resection
Surgically unresectable rectal cancer
Dukes C colon cancer, high risk Dukes B colon cancer, Dukes B rectal cancer or Dukes C rectal cancer (see Appendix 1 for definition of High Risk Dukes B)
Patients with rectal disease
Patients with convincing evidence of extraprostatic extension or T4 disease on digital rectal examination (DRE)
History of prior invasive rectal malignancy, regardless of disease-free interval
Prior significant rectal surgery (hemorrhoidectomy is acceptable)
Rectal fissure, fibrosis, stenosis, or other anatomic abnormality precluding insertion of transrectal device
Prior surgical procedure involving peri-rectal and peri-prostatic area
History of ulcerative colitis or other chronic inflammatory conditions affecting rectum (includes rectal fistula, anal stenosis)
Tumors with a lumen sufficient to allow the positioning of the rectal applicator (standard probe/scope) confirmed by the treating physician
Tumors of less than 4 cm thickness from the rectal mucosa documented at the time of staging images
Previous exposure to chemotherapy for rectal cancer
Digital rectal exam within 90 days of registration on study
Histologically documented adenocarcinoma of the colon; the gross inferior (caudad) margin of the primary tumor must lie above the peritoneal reflection (i.e., patients with rectal cancer are not eligible); surgeon confirmation that the entire tumor was above the peritoneal reflection is only required in cases where it is important to establish if the tumor is a rectal or colon primary
Prior rectal surgery preventing insertion of the TRUS probe.
Any rectal pathology, anomaly or previous treatment, which can change acoustic properties of rectal wall or prevent safe probe insertion (e.g., fistula, stenosis, fibrosis).
Clinical stage T3 or less (pelvic MRI shows no rectal and ureteral invasion)
Clinical stage T4 (pelvic MRI shows rectal and/or ureteral invasion)
History of abdominoperineal resection for rectal cancer, rectal stenosis, or other major rectal pathology
Phase Ib only:\r\n* Patients with metastatic rectal cancer are allowed if their primary site meets other eligibility criteria and chemoradiotherapy is recommended as initial therapy for symptom palliation by the multidisciplinary treating team\r\n* Patients with locally advanced unresectable rectal cancer are allow provided:\r\n** There is no evidence of recto-vaginal, recto-vesicular, recto-intestinal fisutalization\r\n** Standard dose and schedule chemoradiotherapy is recommended as initial therapy by the multidisciplinary treating team
Have pathologically confirmed colon or rectal adenocarcinoma
A histologically confirmed rectal cancer with measurable or evaluable disease on imaging or endoscopy
Any prior radiation for rectal cancer
Rectal/pouch polyposis as a stratification site as follows:
For all subjects, any rectal/pouch polyps > 5 mm must be excised at \baseline\.
prior significant rectal surgery (hemorrhoidectomy is acceptable; rectal resection/fissure repair are excluded);
rectal fibrosis/stenosis; anoscopy or proctoscopy may be performed at the investigator's discretion;
anomaly of the rectal anatomy or mucus membrane; anoscopy or proctoscopy may be performed at the investigator's discretion;
Be undergoing open, or minimally invasive LAR for the treatment of a rectal or rectosigmoid neoplasm (Subjects with rectal or rectosigmoid neoplasm(s) may be treated with or without neoadjuvant therapy. Long-course neoadjuvant therapy must have been completed ?6 weeks prior to LAR surgery (Day 0).
Has previously undergone a rectal resection.
Has recurrent rectal or rectosigmoid cancer.
Has a diagnosis of locally advanced rectal or rectosigmoid cancer undergoing extended en bloc operations.
Has a diagnosis of inflammatory bowel disease (IBD). Subjects with rectal or rectosigmoid cancer neoplasms and IBD are excluded.
Histologically confirmed colon or rectal cancer with metastatic disease
Contraindication to placement of endorectal MRI coil, biopsy device or ultrasound probe (e.g., severe hemorrhoids, anal fissure, recent rectal surgery, or prior abdominoperineal resection)
Evidence of recurrence of rectal cancer prior to the start of study treatment
Prostate size on trans-rectal ultrasound (TRUS) measurement less than 50 grams
Have had prior major rectal surgery (except hemorrhoids).
Receiving chemotherapy (CTX) for breast, colon, rectal, small intestine, or ovarian cancer on a 7, 14, or 21 day schedule with the chemotherapy dose given on day 1
Diagnosis of stage II-III colon or rectal cancer planned for treatment with adjuvant chemotherapy scheduled as part of standard treatment
Eligible patients must have been diagnosed with colon or rectal adenocarcinoma
Diagnosed with pancreatic, esophageal, rectal, colon, hepatobiliary, or gastric cancer (including patients with prior diagnosis of another cancer)
Grade 3 or 4 diarrhea, rectal bleeding, abdominal cramping, or incontinence of stool =< 7 days prior to registration
History of rectal cancer or neoplastic polyp (i.e. intramucosal carcinoma, carcinoma in situ)
Rectal prolapse
Active anal/rectal abscess
Intra-operative injuries (for example: rectal injury)
Have been diagnosed with stage I-III colon or rectal adenocarcinoma
Have not had a clinician-provided digital rectal exam in the prior 3 months
Participants must have endoscopically accessible distal colon and/or rectal mucosa (i.e. participants must have at least part of the descending/sigmoid colon and/or rectum intact).
Cytologically or histologically confirmed of primary colon or rectal adenocarcinoma with resectable cancer, who have not received any treatments for cancer
Known diagnosis of stage III colon or rectal cancer will be excluded from the study
Malignancy or mass that is non-gynecologic in origin (mass/tumor of origin other than reproductive organ such as rectal, abdominal, breast)
Clinical stage =< T2a by digital rectal exam (DRE)
Participants must have endoscopically accessible distal colon and/or rectal mucosa (i.e. participants must have at least part of the descending/sigmoid colon and/or rectum intact)
Any history of current or prior rectal cancer
Any rectal pathology, anomaly or previous treatment, which could change acoustic properties of rectal wall or prevent safe probe insertion (e.g., stenosis, fibrosis, inflammatory bowel disease, etc).
Extracapsular extension suspected on digital rectal exam with confirmation on MRI; suspicion of extracapsular extension on MRI alone is not an exclusion for study enrollment
Symptomatic distal rectal stenosis
Prior abdominopelvic radiation or radiation for rectal cancer
Surgical absence of a rectum or the presence of a rectal fistula
Abnormal digital rectal exam (i.e. palpable nodule, induration or firm area to the prostate)
A diagnosis of histopathologically confirmed rectal adenocarcinoma
Locally advanced disease as determined by endoscopic rectal ultrasound (ERUS) or pelvic MRI; endoscopy reports should clearly state both the T and N stage
Prior receipt of any therapy, including local excision, radiation or chemotherapy, for the diagnosed rectal adenocarcinoma
Suspected stage ? T2 on rectal examination (organ-confined prostate cancer) within the previous 3 months
Diagnosis of rectal cancer
Patient with prior rectal surgery or anal stricture requiring surgical intervention prior to biopsy.
